About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ambrx Appoints Sonja Nelson as Chief Financial Officer

By: via Business Wire

​Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the appointment of Sonja Nelson to Chief Financial Officer.

“I am delighted to welcome Sonja to Ambrx as we expand our executive team, in light of our ongoing expansion,” said Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx. “Sonja brings a breadth of experience in financial operations, planning and strategy from within the biotechnology industry. Her arrival at Ambrx solidifies the company’s management team, and I look forward to leaning on her experience as we transition into the next stages of our company’s development.”

“I would like to thank Dr. Tian and the Ambrx team for welcoming me to the company. I’m excited to be joining Ambrx and impressed by the strength of the company’s development pipeline, and the underlying technology behind it,” said Ms. Nelson. “I look forward to leveraging my experience in the public biotech sector to help provide Ambrx with the financial optionality it needs to further its development pipeline.”

Ms. Nelson is an experienced financial executive, who joins Ambrx with 10 years of executive experience within the biotechnology industry. Most recently, she served as Chief Financial Officer at NantKwest, now ImmunityBio (NASDAQ: IBRX). Prior to NantKwest, Ms. Nelson was Vice President, Corporate Controller for AltheaDx. Previously, Ms. Nelson served as Corporate Controller at Cadence Pharmaceuticals (NASDAQ: CADX, which was acquired by Mallinckrodt plc). Ms. Nelson also served as Director, General Accounting at Cricket Communications, Inc. (acquired by AT&T) between 2008 and 2012. She started her career at KPMG and holds a bachelor’s degree in business administration with specialization in taxation and auditing from the University of Applied Sciences in Pforzheim, Germany. She is a Certified Public Accountant.

About Ambrx

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has collaborations with Bristol Myers Squibb, BeiGene, Sino Biopharma, and NovoCodex, for drug candidates generated using Ambrx technology. For additional information, please visit www.ambrx.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Ambrx’s plans, the future development and potential of Ambrx’s product candidates, and expected contributions of Ms. Nelson. The words “anticipate,” “estimate,” “expect,” “intend,” “may,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks associated with preclinical and clinical development, whether Ambrx will be able to access sufficient funding to execute its business plan, the fact that future clinical results may be inconsistent with prior results, and other factors discussed in the “Risk Factors” section of Ambrx’s registration statement on Form F-1 filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ambrx specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

More News

View More
Microsoft 365 Premium Marks the Next Phase of AI Monetization
Via MarketBeat
Topics Artificial Intelligence
Tickers MSFT
Could Target’s Week of Discounts Come Full Circle for Investors?
Via MarketBeat
Topics Economy
Tickers AAPL GE TGT WMT
3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings
Via MarketBeat
Tickers SFM
Bassett Furniture: Buy Now, Sit Back, and Collect Dividends
Via MarketBeat
Tickers BSET ETD HVT
AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon
Via MarketBeat
Tickers ASTS JOBY RGTI T VOD VZ
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.